Comparison of pulsed Actinomycin versus 5-day Methotrexate for the treatment of low-risk gestational trophoblastic disease in patients

Vice Chancellor for research of Tehran University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Postmolar Gestational trophoblastic neoplasm who meet FIGO stage 1,2,3criteria.
•Patients must have undergone evacuation of a complete or partial hydatidiform mole and then meet the criteria :
•Less than 10% decrease in the ßHCG level using as a reference the first value in the series of 4 values taken over a period of 3weeks ;
•More than 20% sustained rise in the ßHCG taking as a reference the first value in The series of 3 values taken over a period of 2weeks (more than50 );
•Persistently elevated ßHCG level a period of 6 months (more than50 );
•W.H.O. risk score 0-6;
•Patients must have normal hepatic, hematologic, and renal function
•Exclusion criteria:
•Patients who do not have GTN as defined Criteria;
•Patients who have previously been treated with cytotoxic chemotherapy. However, patients who received prior low-dose methotrexate for treatment of an ectopic pregnancy will be eligible for this study;
•Patients with placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT);
•Patients who wish to breast-feed during treatment;
•Patients with non-gestational choriocarcinoma;
•Disease progression;

发起方

Vice Chancellor for research of Tehran University of Medical Sciences